TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04078191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study: NCT06384222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [1-13C] pyruvate (HP 13C)
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational radical prostatectomy (RP)
Description: Planned, standard of care surgical procedure occurring outside of this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT)
Description: Imaging procedure
Study: NCT05617755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-1015
Description: autologous T cell therapy
Study: NCT06131281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-TORe
Description: The E-TORe utilizes ESD in addition to APC prior to endoscopic suturing. In this approach, a standardized solution of normal saline or hetastarch mixed with methylene blue and epinephrine is injected into the gastric rim of the GJA outlet. The mucosa is then carefully incised to expose the underlying muscular layer for a width of approximately 1cm around the GJA circumference. Following ESD, APC is then applied to the inner and outer mucosal margins of the ESD tract. Finally, endoscopic sutures are then placed in purse string fashion and cinched closed around a 6mm TTS balloon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: c-TORe
Description: The c-TORe will be completed utilizing APC prior to endoscopic suturing. In this approach, the gastric rim of the anastomosis is circumferentially ablated using APC (forced APC, flow of 0.8 L/min and power of 30-70 watts) extending an average of 1-2 cm from the outlet. Following ablation, endoscopic sutures are placed in a purse string fashion within the ablated area and the outlet cinched closed over a 6mm through-the scope (TTS) balloon.
Study: NCT06047041

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EIS Only
Description: The EIS Only Condition includes middle schools who have elected to implement the EIS. The EIS:~* Is an online tool to that enables schools to identify students in need of additional mental or behavioral health support and provides recommendations for evidence-based practices.~* Asks teachers and students to report on 7 areas of student social-emotional functioning~* Facilitates schools' understanding of social-emotional student needs and recommended evidence-based practices at a variety of levels (e.g., school-, grade-, and individual-level).~EIS Only Condition supports include:~* Technical assistance professional development sessions to support the implementation of EIS and schoolwide practices related to identifying and supporting student mental health needs.~* Individualized technical assistance for schools to support EIS implementation.
Study: NCT06544668

Intervention type: OTHER
Intervention: Breast cancer patients with bone metastasis
Description: This study is an observational study

Intervention type: OTHER
Intervention: Breast cancer patients without bone metastasis
Description: This study is an observational study
Study: NCT05647083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Classical massage will be applied to the hands and feet, which is expected to take an average of 30 minutes.
Study: NCT06546644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured school-based intervention
Description: A pre-tested validated structured school-based intervention is developed for children in the intervention group. The intervention included behavior change regarding dietary patterns and physical activity. Education will be provided to children in lectures, PowerPoint, smart handouts, and videos. The parents will also be involved in this educational stream through seminars and parent schools specially organized events.
Study: NCT05521763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness
Description: The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness
Description: The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ensuring the availability of influenza vaccine supply & developing influenza vaccine awareness
Description: The four interventions will be:~i) ensuring the availability of influenza vaccine supply; ii) developing influenza vaccine awareness; iii) both ensuring influenza vaccine supply and developing influenza vaccine awareness and iv) control arm with no intervention.
Study: NCT04694989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: QD, PO
Study: NCT05087810

Intervention type: BEHAVIORAL
Intervention: Psychological stress induction
Description: Subjects will undergo acute psychological stress induction by performing mental arithmetic tasks.

Intervention type: OTHER
Intervention: Accelerated oral hydration
Description: Participants will drink 2L of fluid in a short period of time to force diuresis and urine production.
Study: NCT04669873

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard
Description: Radiation: Whole Breast Irradiation + Boost Whole breast, either 40Gy, in 15 fractions, in 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental 1: Hypofractionated radiotherapy
Description: Radiation: Hypofractionated irradiation Whole Breast Irradiation 26Gy in 5 fractions in one week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental 2: Accelerated Partial Breast Irradiation
Description: Radiation: Accelerated partial breast irradiation Tumor bed 26Gy in 5 fractions, in 5 days.
Study: NCT06047041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIS + ECHO
Description: EIS + ECHO supports include supports from the EIS Only condition plus:~* Monthly ECHO sessions for student support teams (SSTs; e.g., interdisciplinary groups of staff tasked to support student mental health). The ECHO experience involves:~  * Didactic training to support EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Case-based learning and collaborative problem-solving related to EIS implementation and effective identification and support of student mental and behavioral health needs.~ * Collaboration with colleagues in schools that are also implementing the EIS.~ * Opportunities to consult with university faculty and content experts in school mental health.~* Individualized SST coaching supports to facilitate the implementation of mental and behavioral health practices and strategies discussed during ECHO sessions.
Study: NCT05525845

Intervention type: OTHER
Group type: OTHER
Intervention: Functional Magnetic Resonance Imaging (pCASL-MRI)
Description: MRI's will be performed at multiple points on each visit day.

Intervention type: OTHER
Group type: OTHER
Intervention: Intragastric Balloon
Description: Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Elemental Meal
Description: Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.

Intervention type: OTHER
Group type: OTHER
Intervention: Hedonic Meal
Description: Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI
Study: NCT05358184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency Percussive ventilation
Description: High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz
Study: NCT05278416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumoral treatment -device and Lumorinse tablets
Description: Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.
Study: NCT05378815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: 3 weekly intra-articular injections of 5mL PRP under ultrasound guidance

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 3 weekly intra-articular injections of 5mL NaCL under ultrasound guidance
Study: NCT06327464

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Exogenous ketones
Description: Consumption of a single exogenous ketone supplement with breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Exogenous ketones
Description: Consumption of a single exogenous ketone supplement with breakfast
Study: NCT05831644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 is an angiotensin II type 2 receptor agonist (ATRAG)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 is an angiotensin II type 2 receptor agonist (ATRAG)
Study: NCT04735419

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05325242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene particles
Description: Embozene particles are FDA approved for the embolization of hypervascular tumors and arteriovenous malformations. Several studies have shown excellent safety and efficacy with regards to tumor control and objective response in liver cancer. It has been used extensively for the treatment of symptomatic uterine fibroids, where Embozene embolization of the uterine arteries results in necrosis of uterine fibroids and cessation of abnormal vaginal bleeding. Other proven uses include embolization of arteriovenous malformations and fistulas.
Study: NCT04805684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LUS Twelve area
Description: Application of 12 areas (2 posterior, 2 lateral, and 2 anterior)lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LUS Fourteen area
Description: Application of 14 areas (3 posterior, 2 lateral, and 2 anterior) lung ultrasonography protocol using the convex ultrasound probe (2-6 MHz)
Study: NCT06300255

Intervention type: BEHAVIORAL
Intervention: H.O.O.V.E.S. Healing Intensives
Description: H.O.O.V.E.S. is a private, donor-supported charity dedicated to providing fully-funded, \[4\]-day, non-clinical healing intensives for veterans, their families and caregivers, and first responders across the nation who are seeking recovery from service-connected stress. 1~References~1. Home. HOOVES for Vets. Accessed January 24, 2024. https://www.hooves.us/.
Study: NCT05461261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given intravenously 75 mg/m2 every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: 5mg Prednisolone Acetate will be given orally twice a day during treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate
Description: 5mg Prednisolone Acetate will be given orally twice a day during treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based drugs
Description: Platinum-based drugs will be given intravenously 70 mg/m2 every 3 weeks for 6 cycles. Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.
Study: NCT04365517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: We propose a randomized controlled open label intervention study. Patients with type 2 diabetes admitted to COVID-19 and randomized to the study group will be treated with sitagliptin at an adjusted dosage for estimated glomerular filtrate: 100 mg once daily (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2 ) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2) in combination or not with insulin. Patients with stage IV and V renal failure (estimated glomerular filtration rate less than or equal to 30 mL / min / 1.73 m2) will be excluded
Study: NCT04894734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EES on
Description: Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EES off
Description: Epidural electrical stimulation (EES), also known as spinal cord stimulation (SCS), is a common FDA-approved therapy for chronic neuropathic pain of trunk and limb.
Study: NCT05835310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Participants will receive a single dose of Anifrolumab via IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo via IV infusion
Study: NCT05268562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 1-2 mg/kg induction with additional medication administered as needed to achieve intubating conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.5-1 mg/kg induction with additional medication administered as needed to achieve intubating conditions
Study: NCT04689256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-010
Description: MR-010 includes a patient application and sensors with commercially available headphones and smartphones. Sensors are placed on the subject's shoes and measure gait metrics. The algorithm uses data from the sensors to inform changes made to the audio cues. These cues, which are embedded in time-shifted music, are delivered back to the users who aim to walk to the beat.
Study: NCT06178055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUS121 high dose
Description: Participants will receive KUS121 high dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUS121 low dose
Description: Participants will receive KUS121 low dose intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Participants will receive a sham procedure that mimics an intravitreal (IVT) injection once on each of 3 consecutive days (Day 1 through Day 3).
Study: NCT06170437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke-free home resident intervention
Description: Study staff delivered intervention on how to adopt a smoke free home using a pamphlet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Worker coaching
Description: Brief tobacco cessation coaching by lay health worker housing staff with residents within 2 weeks of the smoke-free home resident intervention, and on a monthly schedule as part of their routine encounters with residents (total 6 sessions).
Study: NCT05771064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Moves
Description: A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position; and two movements in the standing position. The intervention will be delivered by a research coach.
Study: NCT06642168

Intervention type: GENETIC
Intervention: Whole exome sequencing to detect myocardial genetic mutations (SCA group only)
Description: Whole exome sequencing to detect myocardial genetic mutations
Study: NCT04170907

Intervention type: OTHER
Group type: OTHER
Intervention: standardized vaping protocol
Description: The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.

Intervention type: OTHER
Group type: OTHER
Intervention: standardized vaping protocol
Description: The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.

Intervention type: OTHER
Group type: OTHER
Intervention: standardized vaping protocol
Description: The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
Study: NCT06144125

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fresh frozen plasma
Description: transfusion of fresh frozen plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prothrombin complex concentrate
Description: prothrombin complex concentrate administration
Study: NCT05283148

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-energy X-ray absorptiometry
Description: Measure bone mineral density at the lumbar spine, left total hip, left forearm, and whole body

Intervention type: OTHER
Group type: OTHER
Intervention: Vertebral fracture analysis
Description: Obtain thoracolumbar morphometry in DXA scan, then determine presence and severity of vertebral compression fractures by VFA

Intervention type: OTHER
Group type: OTHER
Intervention: Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
Description: Calculate patient-reported total pain scores to determine the pain phenotype of each study participant
Study: NCT06305078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized ADHD Medication Experiment
Description: All parent/adolescent dyads will select and complete a medication experiment.
Study: NCT05862337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules, Penpulimab injection
Description: Anlotinib hydrochloride capsules is a multitargeted receptor tyrosine kinase inhibitor.~Penpulimab injection is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo
Description: placebo control, no active substance.
Study: NCT05695014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach Back Metod
Description: teach-back method is a way of checking understanding by asking patients to state in their own words what they need to know or do about their health. It is a way to confirm that you have explained things in a manner your patients understand.
Study: NCT06084845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study: NCT05450705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Description: A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.